Egor Mustaev

Mr. Egor Mustaev

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Sergey SedykhSergey Sedykh
Sergey Sedykh
Kseniya AulovaKseniya Aulova
Kseniya Aulova
EMEgor Mustaev
Egor Mustaev
GNGeorgy Nevinsky
Georgy Nevinsky
This study investigated the role of molecular mimicry in the context of autoimmunity associated with viral infection, using SARS-CoV-2 as a model system. A bioinformatic analysis was performed to identify sequence homologies between the SARS-CoV-2 Spike (S) protein and the human proteome, with a specific focus on immunogenic regions to assess potential cross-reactivity. The analysis revealed homologous regions between the viral S protein and several human proteins, including DAAM2, CHL1, HAVR2/TIM3, FSTL1, FHOD3, MYO18A, EMILIN3, LAMP1, and αENaC, which are predicted to be recognizable by B-cell receptors. Such recognition could potentially lead to the production of autoreactive antibodies, which can contribute to the development of autoimmune diseases. Furthermore, the study examined potential autoreactive CD4+ T-cell responses to human protein autoepitopes that could be presented by HLA class II molecules. Several HLA class II genetic variants were computationally associated with a higher likelihood of cross-reactive immune reactions following COVID-19, including HLA-DPA1*01:03/DPB1*02:01, HLA-DPA1*02:01/DPB1*01:01, HLA-DPA1*02:01/DPB1*05:01, HLA-DPA1*02:01/DPB1*14:01, HLA-DQA1*01:02/DQB1*06:02, HLA-DRB1*04:01, HLA-DRB1*04:05, HLA-DRB1*07:01, and HLA-DRB1*15:01. Additionally, seven T helper cell autoepitopes (YSEILDKYFKNFDNG, ERTRFQTLLNELDRS, AERTRFQTLLNELDR, RERKVEAEVQAIQEQ, NAINIGLTVLPPPRT, PQSAVYSTGSNGILL, TIRIGIYIGAGICAG) were identified that could be implicated in autoimmune T-cell responses through presentation by class II HLA molecules. These findings highlight the utility of viral B- and T-cell epitope prediction for investigating molecular mimicry as a possible mechanism in virus-associated autoimmunity.

5 March 2025 in Antibodies
Verified
Journal Article
Open access
PDF file
DSDmitry Shcherbakov
Dmitry Shcherbakov
AIAnastasya Isaeva
Anastasya Isaeva
EMEgor Mustaev
Egor Mustaev
Ebola virus disease (EVD) is an acute illness with a high-case fatality rate (CFR) caused by an RNA virus belonging to the Filoviridae family. Over the past 50 years, regular EVD outbreaks have been reported. The West African EVD outbreak of 2013–2016 proved to be significantly more widespread and complex than previous ones, resulting in approximately 11,000 deaths. A coordinated international effort was required to bring the outbreak under control. One of the main challenges faced by clinicians and researchers combating EVD was the absence of vaccines and preventive treatments. Only recently have efforts led to the development of effective therapeutic options. Among these, monoclonal antibody-based drugs have emerged as the most promising agents for the urgent treatment of EVD. This article aims to review the key milestones in the development of antibody-based therapies for EVD, tracing the journey from the use of convalescent serum to the creation of effective monoclonal antibody-based drugs and their combinations.

7 March 2025 in Antibodies
Verified
Journal Article
Open access
PDF file
VAVazirbek Aripov
Vazirbek Aripov
АЗАнна Владимировна Зайковская
Анна Владимировна Зайковская
LMLudmila V. Mechetina
Ludmila V. Mechetina
ANAlexander M. Najakshin
Alexander M. Najakshin
ABAlexander Bondar
Alexander Bondar
NVNatalya Volkova
Natalya Volkova
Background: Since the emergence of SARS-CoV-2 in the human population, the virus genome has undergone numerous mutations, enabling it to enhance transmissibility and evade acquired immunity. As a result of these mutations, most monoclonal neutralizing antibodies have lost their efficacy, as they are unable to neutralize new variants. Antibodies that neutralize a broad range of SARS-CoV-2 variants are of significant value in combating both current and potential future variants, making the identification and development of such antibodies an ongoing critical goal. This study discusses the strategy of using heterologous antigens in biopanning rounds. Methods: After four rounds of biopanning, nanobody variants were selected from a phage display library. Immunochemical methods were used to evaluate their specificity to the S protein of various SARS-CoV-2 variants, as well as to determine their competitive ability against ACE2. Viral neutralization activity was analyzed. A three-dimensional model of nanobody interaction with RBD was constructed. Results: Four nanobodies were obtained that specifically bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein and exhibit neutralizing activity against various SARS-CoV-2 strains. Conclusions: The study demonstrates that performing several rounds of biopanning with heterologous antigens allows the selection of nanobodies with a broad reactivity spectrum. However, the fourth round of biopanning does not lead to the identification of nanobodies with improved characteristics.

1 January 2025 in Журнал структурной химии
Verified
Journal Article
Closed access
EMEgor Mustaev
Egor Mustaev
ЭХЭ.м. Хамитов
Э.м. Хамитов
В данной работе методами молекулярного моделирования динамически аннотирована полноразмерная третичная структура фермента поли(АДФ-рибоза)-полимеразы 1 (PARP1). Прогнозирование структуры фермента проводилось с использованием известных инструментов, опирающихся на методы машинного обучения и гомологического конструирования. Положение атомов Cα аминокислотных остатков в предсказанных структурах сравнивались с геометрическими параметрами доменов фермента, расшифрованных ранее экспериментальными методами, описанных в научной литературе и депонированных в Protein Data Bank. Результат работы позволяет обосновано выбрать подходящий инструмент прогнозирования, а также использовать геометрические параметры PARP1 для конструирования димерных форм фермента и разработки новых ингибиторов PARP1.